Patrick O'Leary, PhD
Specialist
HDF Comprehensive Cancer Ctr
School of Medicine

Cancer biologist with a focus on using CRISPR screening to develop targeted therapeutics for cancers with mutations in DNA repair genes, and to study mechanisms of resistance to these therapies. Passionate about science education & outreach, strengthening community and exploring the outdoors.

Education & Training

Show all (2) Hide

• PhD Cancer Biology University College Dublin 09/2013
• BSc Pharmacology University College Dublin 06/2009

Publications (11)

Top publication keywords:
ras GTPase-Activating ProteinsMitogen-Activated Protein Kinase KinasesPeroxiredoxinsContractile ProteinsEstrogen Receptor alphaDiterpenes, KauraneOxidative StressNonsense Mediated mRNA DecayBiomarkers, TumorGene Knockdown TechniquesAtaxia Telangiectasia Mutated ProteinsBreast NeoplasmsStomach NeoplasmsTNF-Related Apoptosis-Inducing LigandCarrier Proteins

• Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2.
  Cancer research 2022 O'Leary PC, Chen H, Doruk YU, Williamson T, Polacco B, McNeal AS, Shenoy T, Kale N, Carnevale J, Stevenson E, Quigley DA, Chou J, Feng FY, Swaney DL, Krogan NJ, Kim M, Diolaiti ME, Ashworth A
• RASA2 ablation in T cells boosts antigen sensitivity and long-term function.
  Nature 2022 Carnevale J, Shifrut E, Kale N, Nyberg WA, Blaeschke F, Chen YY, Li Z, Bapat SP, Diolaiti ME, O'Leary P, Vedova S, Belk J, Daniel B, Roth TL, Bachl S, Anido AA, Prinzing B, Ibañez-Vega J, Lange S, …
• A Whole-Genome CRISPR Screen Identifies AHR Loss as a Mechanism of Resistance to a PARP7 Inhibitor.
  Molecular cancer therapeutics 2022 Chen H, Diolaiti ME, O'Leary PC, Rojc A, Krogan NJ, Kim M, Ashworth A
• A protein interaction landscape of breast cancer.
  Science (New York, N.Y.) 2021 Kim M, Park J, Bouhaddou M, Kim K, Rojc A, Modak M, Soucheray M, McGregor MJ, O'Leary P, Wolf D, Stevenson E, Foo TK, Mitchell D, Herrington KA, Muñoz DP, Tutuncuoglu B, Chen KH, Zheng F, Kreisberg JF…
• Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
  BMC cancer 2018 Eustace AJ, Conlon NT, McDermott MSJ, Browne BC, O'Leary P, Holmes FA, Espina V, Liotta LA, O'Shaughnessy J, Gallagher C, O'Driscoll L, Rani S, Madden SF, O'Brien NA, Ginther C, Slamon D, Walsh N, …

Show all (6 more) Hide

• Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents.
  British journal of cancer 2018 Bajor M, Zych AO, Graczyk-Jarzynka A, Muchowicz A, Firczuk M, Trzeciak L, Gaj P, Domagala A, Siernicka M, Zagozdzon A, Siedlecki P, Kniotek M, O'Leary PC, Golab J, Zagozdzon R
• High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.
  Melanoma research 2015 van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, …
• Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.
  Breast cancer research : BCR 2014 O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP…
• Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.
  BMC cancer 2013 O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM
• Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.
  BMC cancer 2012 Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R
• Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
  Pigment cell & melanoma research 2010 Ryan D, Rafferty M, Hegarty S, O'Leary P, Faller W, Gremel G, Bergqvist M, Agnarsdottir M, Strömberg S, Kampf C, Pontén F, Millikan RC, Dervan PA, Gallagher WM